Chemed Corporation (NYSE: CHE) — Two Cash Machines, One Re-Rating: VITAS on Sale, Roto-Rooter on Notice

Date: June 10, 2026 · Price at analysis: ~$438 · Market cap: ~$5.8B · EV: ~$5.8B (net cash) · CIK: 0000019584 Sector: Health Care Services (hospice) + Consumer/Industrial home services · Fiscal year-end: December

The body of this article (Sections 1–15) takes no buy/sell recommendation and states no price target; valuation is discussed only as embedded expectations and scenarios. The single, deliberate exception is the clearly-labeled Claude’s Take block immediately below.

⚡ Claude’s Take

This block is the author’s own independent, subjective opinion and general information only. It is not investment advice. Everything below this block — the analysis in Sections 1–15 — carries no position and no price target, by design.

Verdict: HOLD / accumulate-on-weakness. A genuinely high-quality, net-cash, buyback-driven compounder that has derated ~27% for real (not panic) reasons — but the ~$438 price already reflects most of the good news after an ~11% post-Q1 bounce off the $365 low. The sum-of-the-parts says fair, not cheap; there’s no conglomerate discount left to harvest. I’d want it back toward the high-$300s (its March low) for a clear buy. Fair-value zone ~$400–460; attractive below ~$370; full above ~$500. Not a short — VITAS quality, the buyback engine, and a debt-free balance sheet floor it.

Tag: “Two cash machines, one re-rating — VITAS on sale, Roto-Rooter on notice.”

Chemed is two unrelated, high-ROIC, low-capex cash machines bolted together for one purpose: to feed a relentless, disciplined buyback that has cut the share count ~38% since 2008. The business earns ~24% ROIC, converts >100% of earnings to free cash, carries no net debt, and buys back ~7% of its shares a year — more of them, at lower prices, into weakness (it loaded most of its 2025 repurchases below $440 after the derate). That per-share compounding machine is the real franchise, and at ~18× forward adjusted earnings (vs. a historical high-20s) it looks like a quality compounder on sale.

But two things keep me at HOLD, not BUY. First, the derate is rational and the parts don’t scream cheap. Valuing VITAS and Roto-Rooter separately (they have zero operating synergy), a sum-of-the-parts lands ~$400 base / ~$329 bear / ~$507 bull — the ~$438 price is base-to-slightly-optimistic, with no margin of safety to harvest and the stock already recovered most of its drawdown. Second, the two halves are telling opposite stories, and the weaker one may be structural. VITAS (hospice, ~64% of revenue) is quality-on-sale — demographic demand, a tightening program-integrity regime that throttles new competitors, and genuine scarcity value now that Optum has bought Amedisys — but its growth is increasingly taxed by the Medicare aggregate cap, which tripled to a $27.2m revenue reduction in 2025. Roto-Rooter (home services, ~36%) is the problem and the swing factor: revenue has gone nowhere for three years, EBIT margin collapsed from 23.9% to 17.9%, volumes are falling while price masks it, and — critically — management says Google algorithm changes cut its free/organic leads ~16% as PE-backed roll-ups bid up paid leads. That is the erosion of the search-cost moat itself, not a weather blip, and management guided Roto worse in 2026. And the insiders aren’t buying — CEO McNamara (a persistent discretionary seller) sold into the very weakness the company was repurchasing.

Framing: a quality SOTP compounder at fair value, with a live cyclical-vs-structural question on its weaker half. Conviction: medium. Flips bullish if Roto’s organic-lead and job-count trends stabilize (cyclical confirmed) or VITAS’s scarcity attracts a strategic re-rate. Flips bearish if the Medicare-cap drag re-accelerates in 2027 and Roto keeps losing volume while propping revenue with price — the signature of structural share loss disguised as a cycle.

1. Executive Summary

Chemed is a ~$2.5bn-revenue holding company with two structurally unrelated businesses run on a decentralized model with essentially zero operating synergy: VITAS Healthcare (the largest US for-profit hospice provider, ~64% of revenue, ~94% Medicare-reimbursed) and Roto-Rooter (the #1 US plumbing, drain-cleaning, and water-restoration brand, ~36% of revenue). The logic binding them is purely financial — two high-return, low-capital, uncorrelated cash generators funding a disciplined, counter-cyclical share-repurchase machine that has reduced the diluted share count ~38% since 2008.

The business is genuinely high-quality but currently in an earnings down-cycle. FY2025 consolidated revenue was $2,530m (+4.1%), but GAAP EPS fell ~8% to $18.34 and adjusted EBITDA margin slipped to 18.1% (from 20.7% in 2024). The entire deterioration is Roto-Rooter, whose EBIT fell from $226.8m (2023) to $160.8m (2025) and margin from 23.9% to 17.9% — a textbook operating-deleverage air-pocket, but one with a worrying structural overlay (digital-lead-gen erosion). VITAS, by contrast, grew (revenue +6.5%, EBIT $246.9m, ADC up to 22,338) — though its revenue quality is increasingly capped by the Medicare aggregate cap, whose drag tripled to a $27.2m revenue reduction in 2025.

Returns and the balance sheet are excellent. ROIC is ~24%, ROE ~25%, FCF conversion >100% of net income, and the company is debt-free / net cash (the “~$144m debt” in data aggregators is operating-lease liability). The defining capital-allocation story is the buyback: ~$1.55bn deployed over 2021–2025, accelerating into the 2025 share-price weakness (most dollars spent below $440). The dividend is a token ~0.5% yield (~12% payout) — this is a buyback-driven total-return compounder, not an income stock.

The stock derated ~27% from a 2025 high of ~$562 to a March-2026 low of ~$365, triggered by a Q4-2025 miss (−16.4% in a day) on the Medicare-cap hit and Roto softness; it has since recovered to ~$438 on a Q1-2026 beat and a raised 2026 adjusted-EPS guide of $24.00–24.75 (~13% growth) — a raise driven entirely by VITAS (Roto is guided flat-to-worse). On valuation, CHE trades ~18× forward adjusted EPS (~24× GAAP trailing), ~13× EV/adjusted-EBITDA, ~5.6% FCF yield — derated ~25–35% versus its own history, mid-pack versus peers (hospice peer ADUS ~12×, home-services compounder Rollins ~34×). A sum-of-the-parts frames roughly $329 bear / $400 base / $507 bull versus ~$438; the buyback adds ~6–7% to EPS mechanically, roughly half of the guided per-share growth. This memo carries no recommendation and no price target.

2. Business Overview

2.1 A two-segment holding company with no synergy

Chemed operates two businesses that share nothing operationally — different customers, economics, regulators, and demand drivers — and management says so explicitly (“few integrated business functions”). The rationale is financial: two high-ROIC, low-capex, uncorrelated-demand cash machines whose combined free cash flow funds a relentless buyback. FY2025 consolidated revenue was $2,530m (+4.1%); the segment mix has shifted to VITAS ~64% / Roto-Rooter ~36% (from 58:42 in 2023) as VITAS grew and Roto stalled.

2.2 VITAS Healthcare (hospice) — ~64% of revenue

VITAS is the largest US for-profit hospice provider: 33 Medicare provider numbers across 59 programs in 17 states plus DC (Florida-heavy), serving terminally-ill patients with an interdisciplinary palliative-care model across four levels of care (routine home, continuous, inpatient, respite). FY2025 metrics:

The economics are ADC × days × per-diem, net of the aggregate cap, and the cost base is ~58% labor. The long ALOS with a short median reflects a census skewed by a minority of long-stay (often non-cancer, dementia) patients — the exact profile that drives both profitability and the Medicare-cap and program-integrity risks (§3, §9).

2.3 Roto-Rooter (home services) — ~36% of revenue

Roto-Rooter is the #1 US brand in plumbing, drain cleaning, and water restoration — the category-defining name since 1935 — operating ~356 company-owned and franchise locations covering >90% of the US population, serving both residential and commercial customers via 24/7 emergency response. FY2025: revenue $899.9m (flat), EBIT $160.8m (17.9% margin). The revenue mix spans plumbing repair, drain cleaning, excavation, and water/fire restoration; the business is discretionary, weather-sensitive, and historically high-margin — but margins have compressed sharply (§5, §6).

2.4 Why they’re together — and the break-up question

There is no operating reason; the only synergy is at the holding-company capital-allocation level. This invites a recurring investor question: with VITAS now a scarce, scaled, public hospice asset (Amedisys gone to Optum, Gentiva/Kindred private), is there break-up or strategic-sale optionality? The analytical answer (§10): it is a bull lever, not a margin of safety — real, but management shows no break-up intent.

3. Industry Dynamics

Chemed sits in two unrelated industries, requiring two separate verdicts.

3.1 US hospice — structurally attractive for scaled, compliant incumbents

Hospice is paid primarily by the Medicare hospice benefit on a per-diem basis across four care levels, subject to two key constraints: an annual payment update (FY2026: +2.6%, a 3.3% market basket less 0.7% productivity) and the aggregate Medicare cap (FY2026 ~$35,361 per beneficiary) — a ceiling on total reimbursement per patient that, when a program’s per-patient revenue exceeds it, forces a revenue givecack. The demand backdrop is the most forecastable in healthcare (an aging population, rising hospice penetration of Medicare decedents), and the regulatory regime is currently tightening supply in fraud-heavy markets: a CMS 6-month national enrollment moratorium (May 2026), California’s licensing moratorium to 2027 (with 280+ revocations), and the suspended Special Focus Program. Consolidation has removed public peers (Optum acquired Amedisys for ~$3.3bn; Gentiva/Kindred are private), conferring scarcity value on VITAS.

The caveats are real: a monopsony payer (Medicare ~94% of VITAS revenue), the aggregate cap as a structural governor on the best (densest, longest-stay) programs, low barriers to entry in non-CON states, and a permanent fraud/audit overhang (VITAS itself settled the largest-ever hospice False Claims Act case for $75m in 2017). Verdict: structurally attractive for a scaled, compliant incumbent — but capped, single-payer-dependent, and under an intensifying integrity regime.

3.2 Plumbing / drain / restoration — structurally mediocre, no industry barriers

The US plumbing and drain market is large (~$170bn) and highly fragmented (~132,000 firms, top player <5% share), commoditized, and cyclical (weather- and discretionary-spend-sensitive). There are no industry-level barriers; the only edge is brand and scale. And the capital cycle is deteriorating: a wave of private-equity roll-ups (21+ platforms) is actively adding capacity and — critically — bidding up the cost of digital customer-acquisition leads. Verdict: a structurally mediocre, no-moat-at-the-industry-level business in which only the strongest brand/scale operator earns above-average returns — and that edge is now under digital-channel pressure.

4. Competitive Position

4.1 VITAS — a durable but geographically-bounded, capped moat

In Greenwald’s taxonomy VITAS combines local/metro economies of scale + customer captivity + a regulatory (CON) barrier: in its dense Florida and California metros, route density, 24/7 four-level-of-care capability, and entrenched referral relationships (hospitals, nursing homes, physicians) create a scale-plus-captivity advantage that a sub-scale entrant cannot easily replicate, and Certificate-of-Need laws in key states rent an additional barrier from the state (currently strengthening). The moat shows in the financials — segment pre-tax EBIT is ~31% of segment assets. But it is bounded (it is a collection of local monopolies, not a national one), not a switching-cost or proprietary-technology moat, and economically capped by the Medicare aggregate cap, which claws back the reward for the very density and long-stay census that the moat produces. Durable, but with a ceiling.

4.2 Roto-Rooter — a real but narrowing brand-plus-scale moat

Roto-Rooter is the best-quality moat in the company and sits in the worst industry. The #1 national brand since 1935, a 24/7 emergency-response network, and ~$77m/year of advertising scale create genuine search-cost / habit captivity in emergency plumbing — a consumer with a flooding basement at 2am searches “Roto-Rooter.” But the FY2025 downturn exposed the limit: the brand conferred no pricing power (volumes fell while price merely propped revenue), and — the key finding — the discovery channel is shifting against it. Management disclosed that Google algorithm changes cut Roto’s free/organic leads ~16%, forcing a costlier shift to paid search where PE-backed consolidators “upended the Google market for leads.” If customer discovery migrates from “search the brand” to “search the category” (Google/Angi), the search-cost advantage that underpinned Roto’s pricing power erodes structurally. A real moat, narrowing at the edge.

4.3 Competitive verdict

Two genuine but qualified moats: VITAS durable and demand-protected but capped and single-payer-exposed; Roto-Rooter a strong brand losing some of its discovery-channel advantage to digital lead-gen and PE roll-ups. Neither is a permanent fortress; both are financially-evidenced today.

5. Growth History and Forward Opportunities

5.1 Growth history — mid-single-digit organic, buyback-turbocharged per share

Consolidated revenue compounded ~+5.7%/year from 2019 ($1.82bn) to 2025 ($2.53bn); GAAP EPS ~+5.9%/year and adjusted EPS ~+6.2% — but those figures are depressed by a 2025 trough and flattered by a COVID-anomalous 2020; the longer 2013–2023 record was closer to a ~10–12% adjusted-EPS CAGR, the gap between organic growth (~5–6%) and per-share growth being the buyback machine (share count −38% since 2008).

• VITAS revenue: $1.32bn (2023) → $1.53bn (2024, +16.4%) → $1.63bn (2025, +6.5%). The 2024 surge was not a clean run-rate — it combined a recovery off a 2021–2022 labor-shortage trough (a nurse shortage capped admissions; VITAS ran a $39.2m retention-bonus program) and the April-2024 Covenant acquisition. Days-of-care growth decelerated +14.1% → +5.2% → +2.2% (Q1-2026); normalized organic ADC growth is ~5%, with admissions still +6.9% in Q1-2026 — i.e., comp normalization, not demand failure.
• Roto-Rooter revenue: $949m (2023) → $900m (2024) → $900m (2025) — flat for three years, with EBIT down ~29% from the 2023 peak. The decomposition is the tell: in Q1-2026, drain-cleaning job counts fell ~12% while price rose ~12% — revenue propped by price as volume falls.

Growth verdict: two-speed and moderate/deteriorating. VITAS has high-quality volume growth with a capped revenue ceiling; Roto-Rooter’s growth is low-quality and of questionable durability. Durable per-share compounding depends on the buyback — which the derating actually helps.

5.2 Forward opportunities and 2026 guidance

Management raised 2026 guidance at Q1 to adjusted EPS $24.00–24.75 (~13% growth) — entirely a VITAS story:

• VITAS: ADC growth raised to +4.5–5.5%; revenue growth ex-cap +6.5–7.5%; de-novo Florida programs ramping (Marion/Pasco/Pinellas counties combined 526 admissions “exceeding expectations,” Manatee opening mid-2026); the CMS +2.6% update; and — importantly — Florida cap relief (VITAS added $32.5m to the FL cap cushion in Q1 and expects no 2026 FL cap limitation), suggesting active admission-mix management is containing the flagship program’s cap drag. Plus the scarcity/M&A angle (Covenant is the template bolt-on; the enrollment moratorium protects incumbents).
• Roto-Rooter: revenue guided flat (+3–3.5%, unchanged) and EBITDA margin lowered to 21.5–22.5%. Management is not calling a recovery — the forward Roto story is “stabilize and re-acquire franchises,” not “rebound.”

Forward verdict: the bull case is VITAS (demographics + de-novo + scarcity + supply crackdown); the swing risk is Roto (structurally pressured, guided to get worse). The guidance raise is credible but VITAS-weighted and cap-constrained.

6. Financial Quality

6.1 Five-year segment picture ($000)

(Source: FY2025 10-K, MD&A and Note 2; prior 10-Ks.)

6.2 The Roto-Rooter margin collapse — the central profit-quality red flag

Roto’s EBIT margin fell ~740bp in three years (25.3% → 17.9%), EBIT down ~32%, on operating deleverage against flat revenue plus advertising ($77m, +5.5%), wage inflation, a $5.3m casualty-insurance increase, and a 41.8% jump in implicit price concessions on water-restoration billing (a PwC Critical Audit Matter). This is real, broad-based margin erosion — and it is not a non-GAAP artifact: adjusted EBITDA margin fell 20.7% → 18.1% in lockstep. Economics are not improving with scale right now; they are compressing.

6.3 GAAP vs. adjusted — use GAAP as the anchor

Adjusted diluted EPS ($21.55) exceeds GAAP ($18.34) by ~$3.21, and the gap is mostly stock-based and long-term-incentive compensation add-backs (~$42m pre-tax) — a real, recurring economic expense. The defensible add-backs (amortization of reacquired franchise intangibles ~$9–10m; small episodic legal settlements) are minor. Treat adjusted EPS skeptically and anchor valuation on GAAP (~$18.34) and FCF, not the flattering adjusted figure. (Notably, the compensation plans are measured on an even higher “adjusted EPS” of ~$22.61 — ~23% above GAAP.)

6.4 Returns, cash flow, balance sheet

• Returns: ROE ~25% (down from ~35% in 2021–22 as the down-cycle bites), clean ROIC ~24% — genuinely high on a near-debt-free, asset-light model. The headline ROE is mechanically flattered by the buyback-shrunken equity base ($3.6bn treasury stock vs. ~$1.0bn equity), but ROIC confirms the underlying returns are real.
• Cash flow: excellent — operating cash flow ≥ net income every year, FCF >100% of net income in 2024–25 (~$325m FCF in 2025), capex light (~2.5% of revenue). Earnings are cash.
• Balance sheet: debt-free at year-end 2025 (the “$143.8m debt” in aggregators is operating-lease liability; the term loan was repaid in 2023, the revolver undrawn). Goodwill/intangibles ~$750m (VITAS deals). No pension overhang. (Note: Q1-2026 took a modest $91.2m revolver draw to fund buybacks plus franchise deals — the first meaningful borrowing, worth monitoring.)

6.5 Quality of earnings verdict

High on a cash basis (OCF ≥ NI every year, no accrual divergence, debt-free) but the trajectory is deteriorating, not improving — both segments’ margins fell in 2025. Watch-items: the growing Medicare-cap liability ($13.6m → $30.9m) and the rising water-restoration price concessions. A high-quality compounder in an earnings down-cycle, with disciplined dip-buying partly offsetting the operating fade.

7. Capital Allocation

7.1 The buyback machine — best-in-class and counter-cyclical

The buyback is the equity story. Repurchases by year: $576m (2021), $114m (2022), $74m (2023), $359m (2024), $428m (2025) — ~$1.55bn / ~3.1m shares over five years, shrinking average diluted shares from ~16.0m (2019) to ~14.4m (2025), part of a ~38% reduction since 2008. The discipline is data-proven and counter-cyclical: within 2025, Chemed bought least at the $490–555 highs of prior years and loaded most of its dollars at the year’s lowest prices (e.g., ~279k shares in August at ~$438, 400k in Q4 at ~$436) — after the ~25% derate. Net of ~$37–51m/year of SBC, repurchases dwarf grant dilution, delivering real per-share reduction. At ~18× earnings and net cash, this is highly accretive (~6–7% to EPS mechanically), and more accretive the cheaper the stock.

7.2 Dividend, M&A, leverage

• Dividend: a token but fast-growing payout ($1.56 → $1.80 → $2.20/share over 2023–25), ~0.5% yield, ~12% payout — explicitly subordinate to buybacks.
• M&A: disciplined, accretive bolt-ons — Covenant Care hospice ($85m, April 2024, ~10–11× EBITDA, in-footprint) and recurring small Roto-Rooter franchise reacquisitions (e.g., San Francisco + Fort Worth, ~$20.6m, Q1-2026). No large or overpriced deals; no equity issued — not a roll-up risk.
• Leverage: historically debt-free, funding buybacks from FCF and cash; 2025 capital return was ~142% of FCF (funded by drawing down cash from $178m to $74m), and Q1-2026 added a $91.2m revolver draw — a modest, monitorable shift toward debt-funded repurchasing.

7.3 Incentives and insider signal

• Compensation is shareholder-aligned in design: the annual bonus is keyed to adjusted EPS + return on assets, and the PSUs to 3-year adjusted EPS + relative TSR (no ROIC metric, a minor gap; and the “adjusted EPS” used runs ~23% above GAAP — a watch-item).
• Insider ownership is low (the management group ~3.3%, CEO McNamara ~1.3% — half options); Vanguard (~11%) and BlackRock (~9%) dominate. The “founder/family dynasty with high skin-in-the-game” framing is overstated.
• The insider signal is mildly negative: across 211 Form 4s, the pattern is routine grants/exercises plus net selling and zero open-market purchases. CEO McNamara has been a persistent discretionary (non-10b5-1) seller — six sales from August 2025 to May 2026 at $369–461, i.e., selling into the same weakness the company was aggressively repurchasing. Small relative to holdings, but no insider is corroborating “cheap here” with a personal buy.

7.4 Capital-allocation verdict

Best-in-class capital allocation, with two honest caveats. The disciplined, counter-cyclical buyback is confirmed on the data and is the engine of per-share value; M&A is accretive; the balance sheet is conservative; comp is reasonably aligned. The caveats: (1) the buyback only creates value if intrinsic value per share is stable — buying low into a structurally fading Roto base would lever a declining number; and (2) the absence of any insider buying (indeed persistent CEO selling) sits awkwardly with the “compounder on sale” narrative.

8. Changes and Headwinds — Last Two Years

Net mixed — the bear case is mostly Roto + cap; the bull case is mostly VITAS demographics + scarcity + supply crackdown.

Strengtheners: the Covenant acquisition (2024, accretive); the CMS +2.6% FY2026 update; the May-2026 national enrollment moratorium (protects VITAS incumbency by freezing new competitor supply); the de-novo Florida ramp; the Florida cap-cushion rebuild; accretive dip-buying; and the raised 2026 guidance.

Weakeners: the Roto-Rooter margin collapse + structural digital-lead-gen erosion (guided worse in 2026 — the proximate cause of the derate); the Medicare-cap drag tripling ($8.4m → $27.2m); an unaddressed parent-CEO succession overhang (McNamara, 72, since 1994, no announced successor — though VITAS completed an orderly internal CEO transition to Joel Wherley in 2025); an intensifying FCA/program-integrity regime; and modest new leverage.

The fulcrum is the ~27% derating itself: a Q4-2025 miss (−16.4% in a day) dropped the stock from ~$562 to a $365 low, from which a Q1-2026 beat and raised guide recovered it to ~$438. Whether the changes net “strengthen” or “weaken” depends entirely on whether Roto is cyclical (buy) or structural (avoid) — a genuinely two-sided question, with the Google-lead erosion giving the structural side real teeth.

9. Risk Analysis

Synthesis: the high-likelihood risks (cap ceiling, Roto cyclicality/deleverage, single-payer exposure, conglomerate discount) are mostly medium-impact and largely in the price; the high-impact risks (a sharp Medicare rule change, a new FCA action, single-payer loss) are mostly low-to-medium likelihood tail events. The most under-appreciated risk is #4 (Roto structural share loss via digital lead-gen) because it is disguised as cyclicality — if the organic-lead erosion is permanent, the “buy the Roto trough” thesis is wrong. Total-loss risk is effectively nil (debt-free, two cash-generative businesses, no single binary); the realistic downside is multiple stagnation + a structurally-lower Roto earnings base, not impairment.

10. Valuation Discussion (Embedded Expectations)

No price target. No recommendation.

10.1 Clean multiple reconciliation

At ~$438 (cap ~$5.8bn; net cash, so EV ≈ market cap — the aggregators’ ~15.5× EV/EBITDA wrongly loads ~$237m of operating leases as debt):

CHE has derated ~25–35% below its own historical high-20s multiple — the entire “derate” story. Versus peers it is mid-pack: well above hospice peer ADUS (~12× forward) for higher quality/scale, and far below home-services compounder Rollins (~28× EV/EBITDA).

10.2 Sum-of-the-parts — the key analytical frame

Because the two segments have zero synergy and different economics, the cleanest valuation is to value them separately on segment EBITDA × appropriate multiples → equity per share:

The current ~$438 sits base-to-slightly-optimistic — there is no large conglomerate discount to harvest. Note the strategic anchor: VITAS alone, valued at the Amedisys/Optum take-out multiple (~16–17× EBITDA), is worth ~$325/share by itself — so the market is ascribing roughly the remaining ~$110/share to Roto-Rooter. Break-up/strategic-sale optionality (VITAS as an Optum-style target in a consolidating, scarce hospice market) is real but is a bull lever, not a margin of safety — management shows no break-up intent.

10.3 Embedded expectations

At ~$438 / ~18× forward adjusted EPS the market underwrites only ~3–3.5% perpetual FCF growth / mid-single-digit long-run EPS — i.e., Roto stabilization (neither recovery nor collapse) + continued VITAS-led organic growth + buyback accretion. It is not pricing a Roto recovery (upside) or a structural Roto collapse (downside). Decomposing the guided ~12–15% 2026 per-share growth: roughly half is the buyback (mechanical, ~6–7%) and half is organic (VITAS). That split matters: the per-share engine is durable as long as intrinsic value per share is stable — which loops back to the Roto cyclical-vs-structural question.

10.4 Scenario analysis (bear / base / bull)

The asymmetry is roughly symmetric (~20–25% down / ~15–40% up), and Roto-Rooter is the dominant swing variable (~$160m ↔ ~$210m EBIT is a ~$1bn+ EV swing); VITAS’s range is narrowed by the cap on top and demographics on the bottom.

10.5 The buyback-accretion engine and total-return framing

Deploying ~$400m/year on a ~$5.8bn net-cash cap retires ~6.9% of shares annually at a ~5.6% earnings yield funded by ~0%-cost cash — highly accretive, and more accretive the cheaper the stock. But only ~5–6%/year is sustainably FCF-funded (2025’s 142%-of-FCF return drew down cash and Q1-2026 used a $91.2m revolver draw). Combining the levers, the base-case total return is ~10–12%/year (~4–6% organic + ~5–6% sustainable buyback + ~0.5% dividend, before any re-rate). This is a buyback-driven total-return compounder priced near fair value, where the holder is paid ~double digits to wait on the Roto cyclical-vs-structural resolution.

10.6 Valuation verdict

CHE trades ~18× forward adjusted (~24× GAAP), ~13× EV/EBITDA, ~5.6% FCF yield — derated ~25–35% from its own history but, on a synergy-free SOTP, at fair value rather than a discount. The market prices Roto stabilization; the upside requires a Roto recovery or a VITAS scarcity re-rate, the downside a Roto structural fade plus a re-tightening Medicare cap. Net cash, the buyback engine, and VITAS quality provide a floor; the absence of a conglomerate discount and of insider buying caps the “deep value” case.

11. Variant Perception

Consensus view. A high-quality, net-cash compounder with a best-in-class buyback, temporarily derated on a cyclical Roto-Rooter air-pocket and a one-time Medicare-cap hit — “buy the quality compounder on sale” as VITAS demographics carry it through.

The variant fault line — it splits by segment, and the bear half may be structural. The consensus “cyclical buy” rests on Roto-Rooter mean-reverting. But the evidence (organic leads −16%, volumes falling while price props revenue, PE roll-ups bidding up lead costs, management guiding Roto worse in 2026) argues a meaningful part of Roto’s weakness is structural share loss disguised as a cycle. Meanwhile VITAS’s headline growth is increasingly taxed by the Medicare cap. So the variant-long view is “Roto is cyclical and VITAS re-rates on scarcity”; the variant-short view is “Roto fades structurally and the cap re-tightens, leaving the buyback levering a declining base.”

Strongest bull case. VITAS compounds mid-single-digit ADC on the most forecastable demand curve in healthcare, protected by a supply-throttling integrity regime and worth ~$325/share alone at take-out multiples; Roto’s trough is cyclical and operating leverage snaps EBIT back toward $210m; the buyback retires ~7%/year at a derated price; and the multiple re-rates toward its historical high-20s. → bull (~$500–620).

Strongest bear case. Roto’s digital-discovery moat is permanently impaired (a structurally lower earnings base, not a trough); the Medicare cap re-accelerates as VITAS rebuilds long-stay census; the parent-CEO succession disrupts the capital-allocation discipline that is the thesis; and the buyback levers a fading base while insiders sell. → bear (~$330–360).

The 3–5 assumptions that decide it: (1) Is Roto’s weakness cyclical or structural? (the single highest-value question); (2) does the Medicare-cap drag re-accelerate or stay contained?; (3) VITAS organic ADC durability (~5%); (4) buyback discipline + succession continuity; (5) the multiple — does it hold ~18× or re-rate.

Falsification. Bull breaks if Roto job counts keep falling on rising price (structural confirmed) or the 2027 cap drag re-accelerates. Bear breaks if Roto organic-lead and volume trends stabilize, or a VITAS strategic/scarcity catalyst emerges.

12. Fact vs. Interpretation

13. Open Questions

1. Is the Roto-Rooter organic-lead erosion (−16%) a permanent structural impairment of the brand/search moat, or recoverable via paid-search optimization? The highest-value question — it decides cyclical-buy vs. structural-avoid on ~36% of the business.
2. Will the Medicare-cap drag re-accelerate in 2027+ as VITAS rebuilds ADC/ALOS in capped metros, or has active admission-mix management durably contained it (the $27.2m 2025 hit spanned programs beyond Florida)?
3. Parent-CEO succession — McNamara is 72 with no announced plan; who inherits the capital-allocation discipline that is the thesis?
4. Does VITAS scarcity value (post-Amedisys) + zero synergy create credible break-up/strategic-sale optionality the market is ignoring?
5. Is the new leverage ($91.2m) a one-off (franchise deals) or the start of debt-funded buybacks into a possibly-impaired earnings base?

14. What Must Be True

For the bull case (≈$500–620):

• Roto-Rooter’s weakness proves cyclical (volumes stabilize, operating leverage returns EBIT toward ~$210m); VITAS compounds ~5% ADC with the cap contained; the buyback retires ~7%/year at a derated price; and the multiple re-rates toward the historical high-20s — possibly catalyzed by VITAS scarcity/strategic interest.
• Falsification: Roto job counts keep falling while price props revenue (structural confirmed), OR the 2027 Medicare-cap drag re-accelerates — either breaks the bull.

For the bear case (≈$330–360):

• Roto’s digital-discovery moat is permanently impaired (a structurally lower earnings base), the Medicare cap re-tightens, the multiple stays derated, and the buyback levers a fading base.
• Falsification: Roto organic-lead and volume trends stabilize, OR a VITAS strategic/scarcity re-rate emerges — either breaks the bear.

The hinge for both: the cyclical-vs-structural nature of Roto-Rooter’s demand and the trajectory of the VITAS Medicare cap. Everything else is magnitude around those two — with a ~10–12% buyback-plus-growth total return paying the holder to wait, and net cash plus VITAS quality flooring the downside.

15. Source Appendix

(See the separate, fuller CHE_source_appendix.md. Key primary sources below.)

Primary filings (mirrored locally in output/CHE/sources/; SEC EDGAR, CIK 0000019584):

• Chemed FY2025 Form 10-K, filed 2026-02-27 (che-20251231x10k.htm) — Item 1 (Business: both segments, cap mechanics, payor mix, CON, the 2017 FCA settlement, executive officers), Item 1A (Risk Factors), Item 1C (2025 cyber/PHI breach), Item 7 (MD&A segment revenue/EBIT, Medicare-cap reductions, Roto line decomposition, Covenant, buyback prices), Item 8 (financials, Note 2 segments).
• Form 10-K FY2021–FY2024 — multi-year segment and buyback history; the 2021–22 labor-shortage air-pocket.
• Q1-2026 10-Q (filed 2026-04-28) — segment trends, the $91.2m debt draw, $201m treasury.
• 2026 DEF 14A (proxy) — compensation metrics (adjusted EPS + ROA + relative TSR), beneficial ownership.
• Form 4 corpus (211 filings) — insider sweep (net selling, zero open-market buys).

Transcripts: Q1-2026 earnings call (Apr-24-2026) and Q4-2025 call — 2026 guidance, the Google-lead disclosure, the Florida cap-cushion rebuild. (Treated as hypothesis, validated against filings.)

Peer / sector: UnitedHealth/Optum (UNH) and Humana (HUM) — managed-care / hospice payor-side framing (Optum acquired Amedisys); FirstService (FSV) and Rollins (ROL) — home-services industry context. Public filings and disclosures.

Market data: Yahoo Finance (yfinance) comps & quote, 2026-06-10 (peers ADUS, ROL; AMED null due to the Optum acquisition).

Regulatory / news (web, accessed 2026-06-10): CMS FY2026 Hospice Wage Index Final Rule (+2.6%); CMS national enrollment moratorium (May 2026); DOJ 2017 VITAS $75m FCA settlement; UnitedHealth/Optum–Amedisys acquisition; stock-derating coverage.

This article expresses no buy/sell recommendation and no price target; the Claude's Take block above is a separate, clearly-labeled independent opinion and general information only — not investment advice. Management commentary is treated as hypothesis, validated against filings, financials, and external evidence.

APPENDIX A — Standard Diligence Questionnaire

Chemed Corporation (NYSE: CHE) · Report date 2026-06-10 Supplemental to the analysis above. Fact / Interpretation / Assumption labels applied where it matters. All figures USD.

General

What thoughtful questions have other investors asked about this company? The recurring questions: (1) Is Roto-Rooter’s weakness cyclical or structural (the digital-lead-gen erosion)? (2) Is the Medicare aggregate cap a one-time hit or a structural ceiling on VITAS growth? (3) Is the ~27% derate a buying opportunity or a re-rating to a lower-growth reality? (4) Does the disciplined buyback create value, or is it levering a fading base? (5) Is there break-up/strategic-sale optionality in VITAS given hospice scarcity (Optum bought Amedisys)? (6) Who succeeds McNamara, and does the capital-allocation discipline survive him?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: At a cyclical low — 2025 GAAP EPS fell ~8%; Roto-Rooter EBIT is down ~29% from its 2023 peak and margin at a multi-year trough (17.9% vs 25.3% in 2022). VITAS is nearer mid-cycle. The question is whether Roto’s trough is cyclical (mean-reverting) or a new structural baseline.

Driven by the external environment or internal actions? Interpretation: Both. External: Roto demand is discretionary/weather/housing-sensitive; VITAS is Medicare-rate- and cap-driven. Structural/external: the Google-algorithm lead-gen shift and PE roll-up bidding. Internal: VITAS de-novo expansion, admission-mix management of the cap, and the buyback.

How stable are revenues? Fact/Interpretation: VITAS is highly recurring (demographic, Medicare per-diem) but capped; Roto is recurring-but-cyclical (emergency + discretionary repair). The two are uncorrelated, which smooths the consolidated line — the original conglomerate rationale.

Outlook for products/services? VITAS: positive secular (aging) demand, capped by the Medicare cap. Roto: flat-to-soft (guided +3–3.5% revenue, lower margin in 2026); recovery unguided.

How big will this market be — growing, shrinking, domestic or international? Both 100% US. Hospice is growing (aging + rising penetration); plumbing/restoration is large, fragmented, GDP/housing-cyclical, not structurally growing.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: Hospice — less competitive near-term (supply-throttling integrity regime, CON, consolidation), but a monopsony payer. Plumbing — more competitive (PE roll-ups, digital lead-gen bidding up customer acquisition).

How profitable is the business (ROIC, ROE)? Fact: ROIC ~24%, ROE ~25% — genuinely high on a debt-free, asset-light model; ROE flattered by the buyback-shrunken equity base, but ROIC confirms real returns.

How profitable is the industry — barriers? Fact/Interpretation: Hospice — high margins for scaled incumbents, barriers from CON + Medicare certification + the integrity regime, but a single payer and the cap. Plumbing — no industry barriers (~132k firms, top <5% share); only brand/scale confer above-average returns.

Can the business be easily understood? Yes — two simple service businesses (hospice per-diem; plumbing/restoration jobs) plus a buyback engine.

Can it be undermined by foreign low-cost labor? No — both are local, on-site US services.

Do brands matter? Yes for Roto-Rooter (the #1 emergency-plumbing name) and modestly for VITAS (referral-relationship trust). Roto’s brand advantage is narrowing as discovery shifts to digital channels.

What is the nature of competition? VITAS — local/metro scale and referral density vs. smaller hospices. Roto — the national brand + 24/7 network vs. fragmented local plumbers and PE consolidators competing on digital leads.

Customers’ switching costs? Low in absolute terms; the edge is search-cost/habit captivity (Roto) and referral-relationship + clinical continuity (VITAS), both moderate.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: The VITAS Medicare provider numbers / scale and the Roto brand are valuable, under-recognized intangibles. Conversely, treasury stock ($3.6bn) reflects cumulative buybacks, depressing book equity.

Off-balance-sheet liabilities? Fact: Operating leases (~$144m, mislabeled as “debt” by aggregators); the Medicare-cap liability ($30.9m and growing); ordinary-course FCA/billing-audit exposure (a contingent, history-laden risk).

How conservative is the accounting? Interpretation: GAAP is conservative and cash-backed (OCF ≥ NI every year). The non-GAAP “adjusted” presentation is mildly aggressive (adds back real stock comp) — anchor on GAAP.

How CapEx-hungry is the business? Fact: Light — capex ~2.5% of revenue. Both segments are asset-light services; growth capital goes to de-novo hospice programs and franchise reacquisitions, funded from FCF.

Capital Allocation & Management

How much FCF, and how is it used? Fact: ~$325m FCF (2025), >100% conversion. Used overwhelmingly for buybacks (~$428m in 2025, ~142% of FCF funded by drawing cash), then small bolt-on M&A and a token dividend.

Significant acquisitions recently? Fact: Covenant Care hospice ($85m, April 2024, ~10–11× EBITDA, accretive); recurring small Roto franchise reacquisitions (e.g., SF + Fort Worth ~$20.6m, Q1-2026). Disciplined, no equity issued.

Buying back shares? Fact: Yes — the centerpiece. ~$1.55bn over 2021–25; share count −38% since 2008; counter-cyclical (most dollars at the lowest prices). ~6–7% EPS accretion.

Issuing large amounts of new shares to insiders? Fact: No — SBC modest; buybacks dwarf grant dilution. Net per-share reduction is real.

Compensation policy? Fact: Annual bonus on adjusted EPS + ROA; PSUs on 3-year adjusted EPS + relative TSR — shareholder-aligned (no ROIC metric; the “adjusted EPS” used runs ~23% above GAAP, a watch-item).

Motivations of management? Interpretation: Long-tenured, capital-allocation-focused (McNamara since 1994). But insider ownership is low (~3.3% group, ~1.3% CEO) and the CEO has been a persistent discretionary seller into the weakness — alignment is by comp design more than by skin-in-the-game, and the selling sits awkwardly with “cheap here.”

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? Fact: No — a US-domiciled C-corp common stock (NYSE: CHE); standard treatment.

Dividend policy? Fact: Token (~0.5% yield, ~12% payout), fast-growing but explicitly subordinate to buybacks. This is a buyback-driven total-return compounder, not an income stock.

How profitable is the business? Very (ROIC ~24%), though margins are currently compressing (Roto).

Is net income diverging from cash from operations? Fact: No adverse divergence — OCF ≥ NI every year; earnings are cash. (Adjusted EPS diverges upward from GAAP via SBC add-backs — that is the figure to discount.)

Risks & Downside

What factors would cause the stock to decline? Confirmation that Roto’s weakness is structural (lead-gen erosion permanent); a re-accelerating Medicare-cap drag; an adverse CMS rule or a new FCA action; a disorderly CEO succession; buybacks levering a fading base. (See §9.)

Risk of a catastrophic loss? Interpretation: Low. Debt-free, two cash-generative businesses, no single binary. The severe tail is a VITAS Medicare exclusion from a new FCA action — low probability, high impact.

Chance of a total loss? Interpretation: Effectively nil. The realistic downside is multiple stagnation + a structurally-lower Roto earnings base, not impairment.

Recent News & Events

Has the business environment changed recently? Fact: Yes — (1) the ~27% derate (Q4-2025 miss, −16.4% day; $365 low; Q1-2026 beat + raised guide); (2) the Medicare-cap drag tripling; (3) the Roto digital-lead-gen erosion; (4) the May-2026 CMS national enrollment moratorium (protects VITAS incumbency); (5) Optum’s acquisition of Amedisys reshaping the hospice peer set.

Significant acquisitions? Covenant Care (2024); ongoing small franchise reacquisitions.

Change in accounting policies? No material change.

Recent changes — new markets, facilities, management? VITAS de-novo Florida programs (Marion/Pasco/Pinellas/Manatee); an orderly internal VITAS CEO transition (Joel Wherley, 2025); an unaddressed parent-CEO succession (McNamara, 72); a 6th-amended $450m revolver and the first meaningful ($91.2m) borrowing in Q1-2026.

APPENDIX B — Source Appendix

Chemed Corporation (NYSE: CHE) · Report date 2026-06-10 Primary sources first. The trailing 60-month SEC corpus is mirrored locally in output/CHE/sources/ (git-ignored). All web sources accessed 2026-06-10.

1. Primary filings — SEC EDGAR (CIK 0000019584), mirrored locally

2. Earnings-call transcripts (management commentary — treated as hypothesis)

3. Peer / sector (public filings & disclosures)

4. Market & valuation data

5. Regulatory, industry, and news (web, accessed 2026-06-10)

• CMS FY2026 Hospice Wage Index Final Rule (CMS-1835-F, Aug-2025): +2.6% payment update (3.3% market basket − 0.7% productivity); aggregate cap $35,361.44.
• CMS national hospice/home-health enrollment moratorium (May-13-2026): 6-month freeze on new enrollments + change-of-ownership; anti-fraud task force; ~800 LA-area providers suspended (~$1.4bn).
• DOJ 2017 VITAS/Chemed settlement: $75m (largest-ever hospice False Claims Act case; aggressive-admissions + crisis-care billing) + 5-year Corporate Integrity Agreement (concluded 2023).
• UnitedHealth/Optum–Amedisys acquisition (~$3.3bn) and Gentiva/Kindred going private — the hospice consolidation / VITAS-scarcity backdrop.
• Stock derating coverage: Q4-2025 miss (EPS $6.42 vs ~$7.07; −16.4% one-day drop); 52-week low $365.21 (Mar-27-2026); Q1-2026 beat + raised guide + ~11% pop (Macrotrends, StockTitan, etc.).

6. Analytical frameworks applied

• Competition Demystified (Greenwald & Kahn) — VITAS moat typed as local/metro scale + customer captivity + CON regulatory barrier (durable but bounded and economically capped); Roto-Rooter as a brand-plus-scale search-cost moat narrowing under digital-channel shift.
• Capital Returns (Marathon / Chancellor) — the deteriorating capital cycle in plumbing (PE roll-ups adding capacity / bidding up leads) vs. the tightening supply cycle in hospice (integrity-regime-throttled entry) — opposite capital-cycle dynamics in the two segments.

All non-obvious facts in the memo carry a citation to one of the above. Management commentary (transcripts, IR) was treated as hypothesis and validated against filings and external evidence. No buy/sell recommendation or price target appears in the memo body; the Claude's Take block is a separate, labeled subjective opinion.